ss-31 elamipretide clinical trials SS31 has been shown to be effective for acute kidney injury - NCT05162768 drug SS-31 Elamipretide Clinical Trials: A Comprehensive Overview

Elamipretidedosage The SS-31 elamipretide clinical trials represent a significant area of research and development in the pursuit of novel therapeutic agentsElamipretide (Brand Name FORZINITY™ for Barth .... Elamipretide, also known as SS-31 and previously under development as Bendavia, is a mitochondria-targeting peptide that has garnered considerable attention for its potential to improve mitochondrial function. This drug has been the subject of numerous clinical trials investigating its efficacy and safety across a spectrum of conditions, particularly those linked to mitochondrial dysfunction.

Understanding Elamipretide and its Mechanism

Elamipretide is a mitochondria-targeting antioxidant that selectively interacts with cardiolipin, a phospholipid crucial for the structure and function of the inner mitochondrial membraneSS-31 treatment ameliorates cardiac mitochondrial .... By localizing to this critical cellular component, elamipretide has been shown in preclinical studies and clinical studies to enhance mitochondrial respiration, improve electron transport chain function, and boost ATP production2025年9月19日—The most common side effects identified inclinical trialswere mild-to-moderate injection site reactions. Serious reactions to Forzinity .... Concurrently, it reduces the production of mitochondrial reactive oxygen species, thereby protecting cells from oxidative stress.SS-31 treatment ameliorates cardiac mitochondrial ... This multifaceted mechanism underlies its potential therapeutic applicationsSS-31.

The molecule has been evaluated for its ability to address age-related changes, including those affecting cognition and physiologySS-31 Peptide | Cellular Energy & Repair. Its "superpower properties" have led to more than 20 clinical trials being conducted, registered under names like elamipretide or Bendavia, with phases ranging from I to III.The most common side effects identified inclinical trialsinclude mild-to-moderate injection site reactions.Elamipretidewas approved for medical use in the ... A notable aspect of its development is the FDA approval for certain conditions, signifying its therapeutic promise.

Clinical Trial Landscape for SS-31 Elamipretide

The elamipretide clinical trials have explored its use in various debilitating diseases. A key disease of focus has been Barth Syndrome (BTHS), a rare genetic disorderSS-31 Peptide | Benefits, Safety & Buying Advice [2026]. Clinical trials have provided evidence that SS-31 helped hearts pump stronger, improved muscle function, and enabled affected children to walk farther, fundamentally changing the narrative for these patientsSS31 has been shown to be effective for acute kidney injuryand ischaemia-reperfusion-derived organ damage (Dai et al., 2013), whereas TUDCA is indicated for .... This led to an FDA approval for the first treatment for Barth Syndrome, marking a significant milestone.

Beyond Barth Syndrome, elamipretide is currently undergoing phase 3 clinical trials for primary mitochondrial myopathy and age-related macular degeneration (AMD). Its potential as a treatment for age-related macular degeneration is particularly promising, with SS31 showing potential in this areaElamipretide Topical Ophthalmic Solution for the Treatment .... Furthermore, SS-31 has demonstrated effectiveness in conditions such as acute kidney injury and ischemia-reperfusion-derived organ damage.

However, it's important to note that clinical trials in heart failure and primary mitochondrial myopathy have failed to meet primary endpoints in some instances, highlighting the complex nature of drug development and the variability in patient responses. Despite these setbacks, the overall body of research continues to expandWe are investigatingelamipretide in late stage clinical studiesfor mitochondrial diseases such as Barth Syndrome and orphan diseases with cardiomyopathy..

Key Clinical Trial Investigations and Findings

Several significant studies and trials have contributed to our understanding of SS-31 elamipretide clinical trials:

* NCT03323749: This multicenter, phase 3 randomized, double-blind, parallel-group, placebo-controlled trial was designed to evaluate the safety and efficacy of daily subcutaneous elamipretide.

* TAZPOWER Clinical Trial: The approval of FORZINITY (elamipretide) was supported by efficacy and safety data from the TAZPOWER clinical trial, including an open-label extension that followed patients for up to 168 weeks, detailing long-term efficacy and safety of elamipretide.

* Randomized Dose-Escalation Trial: A randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy (PMM) showed that elamipretide increased exercise performance after 5 days of treatment without significant safety concernsElamipretide Clinical Trials. This particular study involved over 179 citations.

* Leber Hereditary Optic Neuropathy Study: A separate study aimed to assess the safety, tolerability, and potential efficacy of topical elamipretide in patients affected with Leber hereditary optic neuropathy2025年10月10日—The approval of FORZINITY is supported by the efficacy and safety data from the TAZPOWERclinical trial. During the open-label portion of the ....

* Barth Syndrome Phase 2/3 Trial: A phase 2/3 randomized clinical trial followed by an open-label extension was conducted to evaluate the effectiveness of elamipretide in Barth syndrome.

* Preclinical and Clinical Models: Preclinical studies have demonstrated the protective and restorative efficacy of elamipretide in models of heart failure and neurodegeneration. Furthermore, elamipretide increases mitochondrial respiration, improves electron transport chain function, and reduces oxidative stress.

* Human Trials Analysis: An analysis of 18 clinical trials of SS-31 in humans offered a comprehensive overview of both successful and unsuccessful outcomes, contributing to a nuanced understanding of the drug.

Safety and Side Effects

The safety profile of elamipretide has been a consistent focus in all clinical trials. Generally, SS-31 treatment leads to few adverse events, though mostly mildA phase 2/3 randomizedclinical trialfollowed by an open-label extension to evaluate the effectiveness ofelamipretidein Barth syndrome, a genetic disorder of .... The most common side effects identified in clinical trials were mild-to-moderate injection site reactionsSS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease. Serious reactions are rareHowever,no clinical trials are ongoing on this interesting molecule. Elamipretide (SS-31) is a mitochondria-targeted tetrapeptide that selectively interacts .... One study highlighted that in the TAZPOWER OLE, the long-term safety and tolerability of elamipretide were assessed.Study Details | NCT03323749 | A Trial to Evaluate Safety ... Despite some clinical trials in heart failure and primary mitochondrial myopathy having failed, the overall safety data across numerous studies has been encouraging.

Future Directions and Ongoing Research

While FORZINITY has received FDA approval, research into elamipretide continues2021年4月8日—Stealth BioTherapeuticsis planning a Phase 2a clinical trial of elamipretide (SS-31) as a treatment for people with vision loss and/or heart .... Stealth BioTherapeutics was planning a Phase 2a clinical trial of elamipretide (SS-31) for individuals with vision loss and/or heart conditions. Currently, there appear to be some statements suggesting that no clinical trials are ongoing on this interesting molecule, which might refer to specific indications or earlier-stage investigations, as later-stage studies and approvals clearly indicate ongoing and completed trialsElamipretide: A Review of Its Structure, Mechanism of Action ....

The most recent information suggests that the recommended elamipretide dosage based on clinical trials is 40 mg per day administered subcutaneouslyLong-term efficacy and safety of elamipretide in patients ....

In conclusion, the journey of SS-31 elamipretide clinical trials showcases the rigorous process of medical innovation. From extensive studies in laboratory settings to large-scale clinical trials, elamipretide has demonstrated significant potential, leading to crucial FDA approval for certain conditions and offering hope for patients battling mitochondrial diseases and other related ailments. The ongoing research and studies continue to refine our understanding of its therapeutic benefits and expand its potential applications作者：X Du·2024·被引用次数：42—Systematically analyze18 clinical trials of SS-31 in humans, offering a comprehensive overview of both successful and unsuccessful results, contributing to ....